Carlo Piccinni’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


The generic medicines system in Italy: scenarios for sustainable growth
  • Article

September 2016

·

12 Reads

·

2 Citations

Generics and Biosimilars Initiative Journal

Federico Fontolan

·

Silvia Zucconi

·

Carlo Piccinni

In this paper, an overview is provided of the present Italian generic medicines system. Data on generic medicines market share and enterprise performance were reviewed and discussed, and the results of a survey completed by general practitioners (Computer Assisted Web Interview), pharmacists (Computer Assisted Web Interview) and patients (Computer Assisted Personal Interview) are presented. How potential policies on manufacturing and exports affect the industry in Italy are also explored. The results show that generic medicines in Italy have a lower market share than in other major European countries. This is mainly because general practitioners are uncomfortable with generic medicines companies, in particular those whose chain of production is unclear to them. A series of obstacles to diffusion of generic medicines also persists at a legislative level, such as payback and patent linkage. Manufacturing and exports in Italy could benefit from the manufacture of generic medicines before patent expiry, which would enable exports to countries with different expiry dates.

Citations (1)


... The SSN currently only reimburses Class A medicines at the lowest price available: if patients opt to purchase a branded, more expensive version of the drug, the cost difference is paid by the user. Despite such efforts, in 2014 generic medicines accounted for barely 13 percent of spending on Class A medicines, and constituted only 7.7 percent of the total pharmaceutical market in terms of value and 22.1 percent in terms of volume (Piccinni et al. 2016;OECD 2019a). ...

Reference:

Italy.
The generic medicines system in Italy: scenarios for sustainable growth
  • Citing Article
  • September 2016

Generics and Biosimilars Initiative Journal